Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response

References

• Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16:5-24; PMID:21212434; http://dx.doi.org/10.1634/theoncologist.2010-0190
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol: Off J Am Soc Clin Oncol 2009; 27:6199-206; PMID:19917835; http://dx.doi.org/10.1200/JCO.2009.23.4799
   PubMed Web of Science ®Google Scholar
• Lotze MT, Rosenberg SA. The immunologic treatment of cancer. CA: Cancer J Clin 1988; 38:68-94; PMID:2450624; http://dx.doi.org/10.3322/canjclin.38.2.68
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl J Med 1988; 319:1676-80; PMID:3264384; http://dx.doi.org/10.1056/NEJM198812223192527
   PubMed Web of Science ®Google Scholar
• Lee S, Margolin K. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep 2012; 14:468-74; PMID:22878966; http://dx.doi.org/10.1007/s11912-012-0257-5
   PubMed Web of Science ®Google Scholar
• Haanen JB. Immunotherapy of melanoma. EJC Suppl 2013; 11:97-105; PMID:26217118; http://dx.doi.org/10.1016/j.ejcsup.2013.07.013
   PubMedGoogle Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23:515-48; PMID:15771580; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115611
   PubMed Web of Science ®Google Scholar
• Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19:225-52; PMID:11244036; http://dx.doi.org/10.1146/annurev.immunol.19.1.225
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13; PMID:7882171; http://dx.doi.org/10.1016/1074-7613(94)90071-X
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, NY) 1996; 271:1734-6; PMID:8596936; http://dx.doi.org/10.1126/science.271.5256.1734
   PubMedGoogle Scholar
• Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7:445-50; PMID:9354465; http://dx.doi.org/10.1016/S1074-7613(00)80366-0
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proce Natl Acad Sci U S A 2003; 100:8372-7; PMID:12826605; http://dx.doi.org/10.1073/pnas.1533209100
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100:4712-7; PMID:12682289; http://dx.doi.org/10.1073/pnas.0830997100
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med 2015; 7:280sr1; PMID:25810313; http://dx.doi.org/10.1126/scitranslmed.3010274
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, Thompson JA, Balch CM. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Rev 2014; 40:1056-64; PMID:25060490; http://dx.doi.org/10.1016/j.ctrv.2014.06.012
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol: Off J Am Soc Clin Oncol 2015; 33:1889-94; PMID: 25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
   PubMed Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res: Off J Am Assoc Cancer Res 2007; 13:6681-8; PMID:17982122; http://dx.doi.org/10.1158/1078-0432.CCR-07-0187
   PubMed Web of Science ®Google Scholar
• Kong YC, Wei WZ, Tomer Y. Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann New York Acad Sci 2010; 1183:222-36; PMID:20146718; http://dx.doi.org/10.1111/j.1749-6632.2009.05138.x
   PubMed Web of Science ®Google Scholar
• Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116:1767-75; PMID:20143434; http://dx.doi.org/10.1002/cncr.24951
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Danielli R, Calabro L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol, Immunother: CII 2011; 60:467-77; PMID:21170646; http://dx.doi.org/10.1007/s00262-010-0958-2
   PubMed Web of Science ®Google Scholar
• Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol: Off J Euro Soc Med Oncol / ESMO 2013; 24:1697-703; PMID:23439861; http://dx.doi.org/10.1093/annonc/mdt027
   PubMed Web of Science ®Google Scholar
• Chasset F, Pages C, Biard L, Roux J, Sidina I, Madelaine I, Basset-Seguin N, Viguier M, Madjlessi-EzrA N, Schneider P et al. Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. Eur J Dermatol 2015; 25:36-44; PMID:25500362; http://dx.doi.org/10.1684/ejd.2014.2471
   PubMed Web of Science ®Google Scholar
• Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Trans Med 2008; 6:22; PMID:18452610; http://dx.doi.org/10.1186/1479-5876-6-22
   PubMed Web of Science ®Google Scholar
• Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013; 1:229-34; PMID:24777852; http://dx.doi.org/10.1158/2326-6066.CIR-13-0020
   PubMed Web of Science ®Google Scholar
• Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 2015; 6:3479-92; PMID:25682878; http://dx.doi.org/10.18632/oncotarget.2980
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New Engl J Med 2015; 372:2006-17; PMID:25891304; http://dx.doi.org/10.1056/NEJMoa1414428
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397:263-6; PMID:9930702; http://dx.doi.org/10.1038/16717
   PubMed Web of Science ®Google Scholar
• Burmeister Y, Lischke T, Dahler AC, Mages HW, Lam KP, Coyle AJ, Kroczek RA, Hutloff A. ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol 2008; 180:774-82; PMID:18178815; http://dx.doi.org/10.4049/jimmunol.180.2.774
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, Mullen AC, Gasink CR, Kaech SM, Miller JD et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 2005; 6:1236-44; PMID:16273099; http://dx.doi.org/10.1038/ni1268
   PubMed Web of Science ®Google Scholar
• Fritsch RD, Shen X, Sims GP, Hathcock KS, Hodes RJ, Lipsky PE. Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol 2005; 175:6489-97; PMID:16272303; http://dx.doi.org/10.4049/jimmunol.175.10.6489
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17:1290-7; PMID:21926977; http://dx.doi.org/10.1038/nm.2446
   PubMed Web of Science ®Google Scholar
• Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182:311-22; PMID:10653597; http://dx.doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol 2013; 3:107; PMID:23730621; http://dx.doi.org/10.3389/fonc.2013.00107
   PubMedGoogle Scholar
• Mignot G, Hervieu A, Vabres P, Dalac S, Jeudy G, Bel B, Apetoh L, Ghiringhelli F. Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients. PloS One 2014; 9:e105907; PMID:25170840; http://dx.doi.org/10.1371/journal.pone.0105907
   PubMedGoogle Scholar
• Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caraco C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol, Immunother: CII 2014; 63:675-83; PMID:24695951; http://dx.doi.org/10.1007/s00262-014-1545-8
   PubMed Web of Science ®Google Scholar
• Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010; 37:473-84; PMID:21074063; http://dx.doi.org/10.1053/j.seminoncol.2010.09.001
   PubMed Web of Science ®Google Scholar
• Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008; 105:14987-92; PMID:18818309; http://dx.doi.org/10.1073/pnas.0806075105
   PubMed Web of Science ®Google Scholar
• Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res: Off J Am Assoc Cancer Res 2010; 16:2861-71; PMID:20460488; http://dx.doi.org/10.1158/1078-0432.CCR-10-0569
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity 2012; 36:705-16; PMID:22633458; http://dx.doi.org/10.1016/j.immuni.2012.05.008
   PubMed Web of Science ®Google Scholar
• Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10:857-63; PMID:19578369; http://dx.doi.org/10.1038/ni.1767
   PubMed Web of Science ®Google Scholar
• Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res 2011; 317:620-31; PMID:21376175; http://dx.doi.org/10.1016/j.yexcr.2010.12.017
   PubMed Web of Science ®Google Scholar
• Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, Farber JM, Fairchild RL. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol 2007; 178:2278-86; PMID:17277133; http://dx.doi.org/10.4049/jimmunol.178.4.2278
   PubMed Web of Science ®Google Scholar
• Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, Mayer ME, Knaus WA, Mullins DW. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004; 64:7697-701; PMID:15520172; http://dx.doi.org/10.1158/0008-5472.CAN-04-2059
   PubMed Web of Science ®Google Scholar
• Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res: Off J Am Assoc Cancer Res 2009; 15:390-9; PMID:19118070; http://dx.doi.org/10.1158/1078-0432.CCR-08-0783
   PubMed Web of Science ®Google Scholar
• Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res: Off J Am Assoc Cancer Res 2011; 17:4101-9; PMID:21558401; http://dx.doi.org/10.1158/1078-0432.CCR-11-0407
   PubMed Web of Science ®Google Scholar
• Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Euro J Immunol 2013; 43:2797-809; PMID:24258910; http://dx.doi.org/10.1002/eji.201343751
   PubMed Web of Science ®Google Scholar
• Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015; 194:950-9; PMID:25539810; http://dx.doi.org/10.4049/jimmunol.1401686
   PubMed Web of Science ®Google Scholar
• Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 2012; 12:749-61; PMID:23080391; http://dx.doi.org/10.1038/nri3307
   PubMed Web of Science ®Google Scholar
• Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, Banica M, DiCioccio CB, Gross DA, Mao CA et al. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science (New York, NY) 2003; 302:1041-3; PMID:14605368; http://dx.doi.org/10.1126/science.1090148
   PubMedGoogle Scholar
• Lord GM, Rao RM, Choe H, Sullivan BM, Lichtman AH, Luscinskas FW, Glimcher LH. T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood 2005; 106:3432-9; PMID:16014561; http://dx.doi.org/10.1182/blood-2005-04-1393
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ju S, Chen E, Dai S, Li C, Morel P, Liu L, Zhang X, Lu B. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol 2010; 185:3174-83; PMID:20713880; http://dx.doi.org/10.4049/jimmunol.1000749
   PubMed Web of Science ®Google Scholar
• Hegel JK, Knieke K, Kolar P, Reiner SL, Brunner-Weinzierl MC. CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin. Euro J Immunol 2009; 39:883-93; PMID:19224637; http://dx.doi.org/10.1002/eji.200838770
   PubMed Web of Science ®Google Scholar
• Li G, Yang Q, Zhu Y, Wang HR, Chen X, Zhang X, Lu B. T-Bet and eomes regulate the balance between the effector/central memory T cells versus memory stem like T cells. PloS One 2013; 8:e67401; PMID:23826287; http://dx.doi.org/10.1371/journal.pone.0067401
   PubMed Web of Science ®Google Scholar